NCT04222062
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have up to four brain metastases in number & up to 4 cm in size with surgical resection planned for only one
Exclusions: Patients with prior whole brain radiation therapy; Patients with leptomeningeal disease
https://clinicaltrials.gov/show/NCT04222062